Trifluoroacetic Acid
Trifluoroacetic acid is a corrosive organofluorine compound that is structurally analogous to, but stronger than, acetic acid. Available in various quantities and reagent grades, it is used in NMR spectroscopy, mass spectrometry, organic synthesis, etc.
Almost 100,000-fold more acidic than acetic acid, TFA is widely used in organic chemistry. TFA is used as a reagent in organic synthesis because of its properties: volatility, organic solvent solubility, and acidic strength. It is less oxidizing than sulfuric acid and is more readily available in its anhydrous form than some other acids . Other features include:
- Used in acid-catalyzed reactions, especially peptide synthesis (to cleave esters)
- Dissolves protein when mixed with liquid SO2
- Removes t-butyl derived side-chain protecting groups in Fmoc peptide synthesis
- Can remove the t-butoxycarbonyl protecting group in organic synthesis
- At low concentrations, acts as an ion-pairing agent for peptides and small proteins in organic compound liquid chromatography
- For acid-stable materials, can be a solvent for NMR spectroscopy
- Acts as a calibrant in mass spectrometry
- Used to produce trifluoroacetate salts
- An ingredient in adhesives, sealants, paints, and coatings
When TFA combines with bases and metals, especially light metals, a strong exothermic reaction occurs. When mixed with lithium aluminum hydride (LAH), the reaction is explosive.
Although nonflammable, TFA is corrosive to skin, eyes, and mucous membranes and requires careful use and handling. It is harmful when inhaled, causes severe skin burns and eye damage, and is toxic to aquatic organisms at even low concentrations.
TFA is also a product of the metabolic breakdown of the anesthetic agent halothane. It is the suspected cause of halothane-induced hepatitis.
Medchemexpress LLC xStAx-VHLL TFA | 100.0% | 3231.89 | 5 MG
xStAx-VHLL TFA is a β-catenin PROTAC degrader that promotes ubiquitination and proteasome degradation of β-catenin. It inhibits the Wnt/β-catenin signaling pathway. xStAx-VHLL TFA can also inhibit the proliferation of colon cancer cells and demonstrates anti-tumor activity.
- Induces β-catenin degradation in a dose-dependent manner in colorectal cancer cells in vitro
- Inhibits cell proliferation in vitro
- Inhibits Wnt/β-catenin signaling in HEK293T cells in vitro
- Shows antitumor activity in a mouse intestinal tumor model in vivo
- Reduces tumor number and active β-catenin protein levels in APC min/+ mice in vivo
Medchemexpress LLC Pyridostatin (TFA) | 1472611-44-1 | 1037658 | C33H33F3N8O7 | 25 MG
Pyridostatin TFA is a G-quadruplex DNA stabilizing agent with a Kd of 490 nM, targeting both DNA and RNA G4s within cells. This selective small molecule promotes growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage and affects proto-oncogene Src.
- Targets DNA and RNA G4s in cells
- Promotes growth arrest in human cancer cells
- Induces replication- and transcription-dependent DNA damage
- Reduces SRC protein levels and cellular motility in breast cancer cells
- Causes neurite retraction, synaptic loss, and dose-dependent neuronal death in cultured primary neurons
- Induces DNA DSBs in cultured primary neurons
- Downregulates BRCA1 protein at the transcriptional level
- High purity: 99.17%
- Solid, white to off-white appearance
Apexbio Technology LLC cyclo(RLsKDK) TFA(Synonyms: cyclo(RLsKDK), Cyclic peptide RLsKDK, ADAM8 inhibitor peptide, Cyclo-Arg-Leu-Ser-Lys-Asp-Lys), 1mg.
Cyclo(RLsKDK) TFA is a cyclic pentapeptide inhibitor targeting the metalloproteinase ADAM8 a transmembrane protein frequently dysregulated in pathological conditions such as inflammation cancer and neurodegenerative diseases By specifically inhibiting ADAM8 enzymatic activity cyclo(RLsKDK) TFA may modulate disease-associated cellular processes This molecule holds promise as a research tool for studying ADAM8 function and as a potential therapeutic candidate in inflammatory disorders and oncology
eMolecules Ambeed / 2-Fluoro-6-methylpyridine / 5g / 552650211 / A211927 / / 407-22-7 / MFCD00041226 / 111.119 / C6H6FN
Ambeed / 2-Fluoro-6-methylpyridine / 5g / 552650211 / A211927 / / 407-22-7 / MFCD00041226 / 111.119 / C6H6FN
Medchemexpress LLC Pf15 TFA | 99.7% | 969.97 | C46H50F3N13O8 | 5 MG
A heterobifunctional PROTAC that recruits cereblon to promote degradation of FLT3-ITD. It reduces FLT3 and STAT5 phosphorylation, inhibits proliferation of FLT3-ITD-positive cells, and shows tumor growth inhibition in preclinical models. Supplied as a trifluoroacetic acid salt for laboratory research.
Medchemexpress LLC Charybdotoxin TFA | 96.8% | 4295.89 (free acid) | 100 UG
Charybdotoxin TFA is a 37-amino acid peptide that functions as a potassium channel blocker. This compound is a valuable tool for research involving potassium channels.
- Acts as a potassium channel blocker
- 37-amino acid peptide
- Useful for studying potassium channels
- Storage conditions for powder: -80°C for 2 years, -20°C for 1 year
- Storage conditions for in solvent: -80°C for 6 months, -20°C for 1 month
- Sealed storage, away from moisture and light required for both forms
Medchemexpress LLC ATX-II TFA | 99.7% | 4934.62 | 500 UG
ATX-II TFA is a selective sodium channel modulator toxin that enhances late sodium current, prevents full sodium channel inactivation, and generates persistent current fractions. It has a pro-arrhythmic effect, slowing intrinsic heart rate and prolonging QT interval. This compound is suitable for research on atrial fibrillation, long QT syndrome, and long QT3 syndrome.
Medchemexpress LLC Lagipra peptide (TFA) | 98.2% | 5756.50 (free base) | 1 MG
LAGIPRA peptide TFA is a long-acting GIP1R agonist. It enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. This peptide has potential for the research of type 2 diabetes.
- Long-acting GIP1R agonist
- Enhances insulin sensitivity
- Reduces branched-chain amino acids (BCAAs)
- Reduces ketoacids
- Potential for type 2 diabetes research
Medchemexpress LLC TP-5801 (TFA) | 99.6% | 641.48 | 100 MG
TP-5801 TFA is an orally active TNK1 (non-receptor tyrosine kinase) inhibitor with an IC50 of 1.40 nM, demonstrating anti-tumor activity. It inhibits TNK1-driven, BCR-ABL-driven, and IL-3-driven Ba/F3 cell growth, and TNK1-dependent L540 cell growth.
- Orally active
- Potent TNK1 inhibitor (IC50=1.40 nM)
- Demonstrates anti-tumor activity
- Inhibits growth of various cell lines (Ba/F3 and L540) relevant to TNK1-driven processes
- Shows efficacy in animal models, prolonging lifespan and inhibiting localized tumor growth without signs of toxicity
![Medchemexpress LLC Benzamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-2,5-dimethoxy-, 2,2,2-trifluoroacetate | 1336913-03-1 | 99.9% | 404.38 | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000438811-Logo.png-250.jpg){kind=logo}
Medchemexpress LLC Benzamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-2,5-dimethoxy-, 2,2,2-trifluoroacetate | 1336913-03-1 | 99.9% | 404.38 | 25 MG
PSEM 89S TFA is a selective and brain penetrant agonist for ion channels, orthogonally selective for Q79G and L141F. It is intended for research use only.
- Activates layer 2/3 cortical neurons expressing PSAML141F,Y115F-5HT3 high conductance.
- Reversibly silences transfected neurons by reducing cellular input resistance.
- Reduces photostimulation-evoked feeding in mice with PSAML141F,Y115F-glycine receptor.
- Demonstrates good brain penetrance in mice after intraperitoneal administration.
- Suppresses fos in ChR2-expressing neurons in Agrp-cre mice.
- Shows rapid rise in serum and brain, cleared within 1 hour in C57BL/6 mice.
Medchemexpress LLC Alvespimycin (17-DMAG) trifluoroacetate | 00-00-0 | MFCD08457919 | 99.0% | 730.77 g/mol | C34H49F3N4O10 | 5 MG
Alvespimycin TFA is the trifluoroacetate salt of 17-DMAG, a small-molecule inhibitor of heat shock protein 90 (Hsp90) used as a research reagent to study Hsp90-dependent signaling and anticancer mechanisms. The compound binds Hsp90 with an EC50 of 62 nM and is supplied as a high-purity, pale purple solid for laboratory use.
- Potent Hsp90 inhibitor (EC50 62 nM).
- Trifluoroacetate (TFA) salt form for consistent handling.
- High purity (reported ~98.97%).
- Molecular weight 730.77 g/mol.
- Pale purple solid appearance.
- Storage: sealed, away from moisture and light; in solvent, -80°C (6 months) or -20°C (1 month).
Medchemexpress LLC AH-D peptide TFA | 98.8% | 3283.75 | 5 MG
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
- Antiviral peptide
- Disrupts membrane structures within exosome size range
- Induces T-EXO depletion
- Enhances cancer immunotherapy
- Solid, white to off-white appearance
- Store sealed, away from moisture
- Powder storage at -80°C for 2 years, -20°C for 1 year
- In solvent storage at -80°C for 6 months, -20°C for 1 month